Neil F. McFarlane - 29 Jan 2026 Form 4 Insider Report for ZEVRA THERAPEUTICS, INC. (ZVRA)

Role
President and CEO, Director
Signature
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Neil F. McFarlane
Issuer symbol
ZVRA
Transactions as of
29 Jan 2026
Net transactions value
-$853,425
Form type
4
Filing time
02 Feb 2026, 17:18:52 UTC
Previous filing
10 Oct 2025
Next filing
10 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
McFarlane Neil F. President and CEO, Director C/O ZEVRA THERAPEUTICS, INC., 1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Neil F. McFarlane 02 Feb 2026 0001681098

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZVRA Common Stock Options Exercise +233,334 +105% 455,350 31 Jan 2026 Direct F1
transaction ZVRA Common Stock Sale $853,425 -91,000 -20% $9.38 364,350 02 Feb 2026 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZVRA Restricted Stock Unit Award $0 +125,000 $0.000000 125,000 29 Jan 2026 Common Stock 125,000 Direct F1, F4
transaction ZVRA Stock Option (right to buy) Award $0 +250,000 $0.000000 250,000 29 Jan 2026 Common Stock 250,000 $8.86 Direct F5
transaction ZVRA Restricted Stock Unit Options Exercise $0 -233,334 -50% $0.000000 233,333 31 Jan 2026 Common Stock 233,334 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Adoption date of referenced 10b5-1(c) plan is: 03-21-2025.
F3 This transaction was executed in multiple trades at prices ranging from $8.94 to $9.53. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.
F5 Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
F6 One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date.